236 related articles for article (PubMed ID: 9916055)
1. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.
Giannasca PJ; Zhang ZX; Lei WD; Boden JA; Giel MA; Monath TP; Thomas WD
Infect Immun; 1999 Feb; 67(2):527-38. PubMed ID: 9916055
[TBL] [Abstract][Full Text] [Related]
2. Systemic antibody responses induced by a two-component Clostridium difficile toxoid vaccine protect against C. difficile-associated disease in hamsters.
Anosova NG; Brown AM; Li L; Liu N; Cole LE; Zhang J; Mehta H; Kleanthous H
J Med Microbiol; 2013 Sep; 62(Pt 9):1394-1404. PubMed ID: 23518659
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters.
Torres JF; Lyerly DM; Hill JE; Monath TP
Infect Immun; 1995 Dec; 63(12):4619-27. PubMed ID: 7591115
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of Clostridium difficile Toxin B Mediated by Engineered Lactobacilli That Produce Single-Domain Antibodies.
Andersen KK; Strokappe NM; Hultberg A; Truusalu K; Smidt I; Mikelsaar RH; Mikelsaar M; Verrips T; Hammarström L; Marcotte H
Infect Immun; 2016 Feb; 84(2):395-406. PubMed ID: 26573738
[TBL] [Abstract][Full Text] [Related]
5. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
[TBL] [Abstract][Full Text] [Related]
6. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B.
Permpoonpattana P; Hong HA; Phetcharaburanin J; Huang JM; Cook J; Fairweather NF; Cutting SM
Infect Immun; 2011 Jun; 79(6):2295-302. PubMed ID: 21482682
[TBL] [Abstract][Full Text] [Related]
7. Active and passive immunization against Clostridium difficile diarrhea and colitis.
Giannasca PJ; Warny M
Vaccine; 2004 Feb; 22(7):848-56. PubMed ID: 15040937
[TBL] [Abstract][Full Text] [Related]
8. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
[TBL] [Abstract][Full Text] [Related]
9. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein.
Ní Eidhin DB; O'Brien JB; McCabe MS; Athié-Morales V; Kelleher DP
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):207-18. PubMed ID: 18093141
[TBL] [Abstract][Full Text] [Related]
10. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.
Anosova NG; Cole LE; Li L; Zhang J; Brown AM; Mundle S; Zhang J; Ray S; Ma F; Garrone P; Bertraminelli N; Kleanthous H; Anderson SF
Clin Vaccine Immunol; 2015 Jul; 22(7):711-25. PubMed ID: 25924765
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.
Yang Z; Ramsey J; Hamza T; Zhang Y; Li S; Yfantis HG; Lee D; Hernandez LD; Seghezzi W; Furneisen JM; Davis NM; Therien AG; Feng H
Infect Immun; 2015 Feb; 83(2):822-31. PubMed ID: 25486992
[TBL] [Abstract][Full Text] [Related]
13. Clostridium difficile flagellin FliC: Evaluation as adjuvant and use in a mucosal vaccine against Clostridium difficile.
Bruxelle JF; Mizrahi A; Hoÿs S; Collignon A; Janoir C; Péchiné S
PLoS One; 2017; 12(11):e0187212. PubMed ID: 29176760
[TBL] [Abstract][Full Text] [Related]
14. Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.
Cole LE; Li L; Jetley U; Zhang J; Pacheco K; Ma F; Zhang J; Mundle S; Yan Y; Barone L; Rogers C; Beltraminelli N; Quemeneur L; Kleanthous H; Anderson SF; Anosova NG
Vaccine; 2019 Jun; 37(29):3892-3901. PubMed ID: 31122858
[TBL] [Abstract][Full Text] [Related]
15. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.
Sougioultzis S; Kyne L; Drudy D; Keates S; Maroo S; Pothoulakis C; Giannasca PJ; Lee CK; Warny M; Monath TP; Kelly CP
Gastroenterology; 2005 Mar; 128(3):764-70. PubMed ID: 15765411
[TBL] [Abstract][Full Text] [Related]
16. A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.
Wang H; Sun X; Zhang Y; Li S; Chen K; Shi L; Nie W; Kumar R; Tzipori S; Wang J; Savidge T; Feng H
Infect Immun; 2012 Aug; 80(8):2678-88. PubMed ID: 22615245
[TBL] [Abstract][Full Text] [Related]
17. Development of vaccine for Clostridium difficile infection using membrane fraction of nontoxigenic Clostridium difficile.
Senoh M; Iwaki M; Yamamoto A; Kato H; Fukuda T; Shibayama K
Microb Pathog; 2018 Oct; 123():42-46. PubMed ID: 29959036
[TBL] [Abstract][Full Text] [Related]
18. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults.
Sheldon E; Kitchin N; Peng Y; Eiden J; Gruber W; Johnson E; Jansen KU; Pride MW; Pedneault L
Vaccine; 2016 Apr; 34(18):2082-91. PubMed ID: 26993331
[TBL] [Abstract][Full Text] [Related]
19. Active and passive immunization to protect against antibiotic associated caecitis in hamsters.
Fernie DS; Thomson RO; Batty I; Walker PD
Dev Biol Stand; 1983; 53():325-32. PubMed ID: 6873474
[TBL] [Abstract][Full Text] [Related]
20. Clostridium difficile Toxoid Vaccine Candidate Confers Broad Protection against a Range of Prevalent Circulating Strains in a Nonclinical Setting.
Quemeneur L; Petiot N; Arnaud-Barbe N; Hessler C; Pietrobon PJ; Londoño-Hayes P
Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29632249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
